Oncolytics Biotech, Inc. (Nasdaq: ONCY) has completed patient enrollment in a Phase 2 clinical trial evaluating intravenous administration of REOLYSIN ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE